Tammuella Chrisentery-Singleton/LinkedIn
Aug 8, 2026, 20:37
Tammuella Chrisentery-Singleton: What Comes Next for Hemophilia Care With Non-Factor Therapies?
Tammuella Chrisentery-Singleton, Chief Science Officer at American Thrombosis and Hemostasis Network (ATHN), Co- Director Hemostasis and Thrombosis Program at Ochsner Health, shared a post on LinkedIn:
“After the long trip home from ISTH, I’m excited to bring new insights back to the clinic as we think about what comes next for
hemophilia care with non-factor therapies now being available across the world.
Note: This content is intended for healthcare professionals only.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments